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Abstract Caveolins have been identi¢ed as key components of
caveolae, specialized cholesterol-enriched raft domains visible as
small £ask-shaped invaginations of the plasma membrane. In
polarized MDCK cells caveolin-1 and -2 are found together
on basolateral caveolae whereas the apical membrane, where
only caveolin-1 is present, lacks caveolae. Expression of a cav-
eolin mutant prevented the formation of the large caveolin-1/-2
hetero-oligomeric complexes, and led to intracellular retention
of caveolin-2 and disappearance of caveolae from the basolat-
eral membrane. Correspondingly, in MDCK cells over-express-
ing caveolin-2 the basolateral membrane exhibited an increased
number of caveolae. These results indicate the involvement of
caveolin-2 in caveolar biogenesis.
) 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Besides being components of apical and basolateral trans-
port carriers [1^4], caveolin-1 and -2 have also been identi¢ed
as structural components of caveolae [4^7]. Caveolins and
caveolae have been implicated in a number of cellular process-
es including signal transduction, cholesterol homeostasis and
transport [4,8^14]. In MDCK cells, caveolin-1 is present in
both the apical and basolateral plasma membrane domains,
whereas the expression of caveolin-2 is restricted to the baso-
lateral membrane. There, caveolin-1 and -2 are found in cav-
eolae [4]. Shortly after their synthesis in the endoplasmic
reticulum, the caveolins assemble into caveolin-1 homo-
oligomers and caveolin-1/-2 hetero-oligomers. During their
transit through the Golgi complex [4,7] the oligomers increase
in size [15] and become incorporated in special membrane
domains termed rafts [13]. The oligomeric complexes segre-
gate in the trans-Golgi network, where caveolin-1 homo-olig-
omers are sorted into the apical transport carriers, and the
caveolin-1/-2 hetero-oligomers are directed to the basolateral
route [4]. Several caveolin truncation mutants have recently
been created in order to analyze the targeting of caveolins and
also to ¢nd potential mutants inhibiting caveolin function
[16,17]. One of the characterized mutants, caveolin-3-DGV-
HA (DGV), lacks the 53 N-terminal amino acids upstream
of the sca¡olding domain. This mutant was used to analyze
the role of caveolins in caveolar biogenesis in polarized
MDCK cells.
2. Materials and methods
2.1. Cell culture
MDCKII cells were grown on 12 or 24 mm diameter Transwell
¢lters for 2^3 days prior to use as described previously [18]. For
MDCK cells stably expressing c-myc-tagged caveolin-2 (clone 54 [4])
0.5 mg/ml G-418 was added to the medium.
2.2. Construction of recombinant Cav-3-DGV-HA adenovirus and
adenoviral infections
The cDNA of caveolin-3-DGV-HA [16] was transferred from pCB6
vector to pShuttle-CMV vector using KpnI and XbaI restriction sites,
and recombinant adenovirus was constructed and propagated in 293
cells as described [19]. MDCK cells grown on 12 mm ¢lters were
infected with recombinant adenovirus from the apical side in 200 Wl
volume of infection medium (MEM supplemented with 0.2% bovine
serum albumin and 20 mM HEPES, pH 7.4). For 24 mm diameter
¢lters 1 ml of infection medium was used. After 12 h incubation, the
infection medium was replaced by growth medium and the cells were
used for experiments 3 days post infection.
2.3. Antibodies
Polyclonal anti-caveolin-1 (N-20) and anti-HA tag antibodies (HA
probe) were from Santa Cruz. Monoclonal anti-HA antibodies were
ammonium sulfate precipitated from hybridoma C12A5 supernatant.
Anti-caveolin-2 antibodies (#1825) have been described previously [4].
Secondary FITC- or TRITC-conjugated antibodies were purchased
from Jackson ImmunoResearch.
2.4. Immuno£uorescence and quantitation
Immuno£uorescent labelling was performed as described [4] and the
cells were viewed under a Zeiss LSM410 confocal microscope. To
quantitate the di¡erence in £uorescent signal between control and
DGV-expressing cells, samples with 50% infection frequency were
used. The original x,y-images were opened in NIH image, rendering
£uorescence values from 0 to 256. The £uorescence intensity at the
basolateral membrane was measured at ¢ve rectangular sites of DGV-
expressing or control cells. From the same cells the mean apical £uo-
rescence was measured at a di¡erent z-plane. Measurements were
performed on at least 15 cells from each group. Statistical di¡erences
were tested using a Student’s t-test or a Welch test if the variances of
the groups were not equal. Di¡erences between groups were called
statistically signi¢cant when P6 0.05.
2.5. Biochemical assays
Metabolic labelling of cells was carried out for 18 h with 300 WCi
[35S]methionine per 3 cm dish, whereafter the cells were solubilized
and the samples were immunoprecipitated and subjected to gel elec-
trophoresis as described [4]. Isoelectric focusing was performed as
described [1]. Sucrose velocity gradient centrifugation in SDS^Triton
X-100 was performed as described [4].
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2.6. Electron microscopy and quantitation of caveolae
MDCK cells were ¢xed with 2.5% glutaraldehyde in 0.1 M cacody-
late bu¡er and processed for Epon embedding and electron micros-
copy according to standard protocols (see e.g. [20]). For quantitation
of the number of caveolae, ¢lters with an infection frequency of
s 95% were analyzed. Caveolae were recognized by their 50^80 nm
£ask-shaped structure as described [8,21]. The number of caveolae per
Wm plasma membrane length was calculated following the criteria
described previously [22]. A general di¡erence between control,
DGV-expressing and caveolin-2-over-expressing cells was tested using
a one-factor ANOVA test. Di¡erences between speci¢c cell types were
tested using a Welch test since the variances between the groups were
not equal. Di¡erences between groups were called statistically signi¢-
cant when P6 0.05.
3. Results and discussion
The caveolin mutant DGV has recently been described to
localize to the Golgi complex and distinct lipid droplets after
transfection into BHK cells [16,17]. We constructed a re-
combinant adenovirus encoding DGV in order to control
the frequency and level of expression. Consistent with pre-
vious data [17] DGV was localized in the perinuclear region
corresponding to the Golgi complex and lipid droplets in po-
larized MDCK cells (Fig. 1). As described previously [4] cav-
eolin-1 was detected at both the apical and basolateral plasma
membrane while caveolin-2 was restricted to the basolateral
membrane in control cells (Fig. 1B,A, respectively). In DGV-
expressing cells, caveolin-2 was surprisingly not detectable at
the plasma membrane but retained intracellularly. As in BHK
cells [17], it co-localized to a large extent with DGV in the
perinuclear region (Fig. 1A). The localization of caveolin-1 in
DGV-expressing cells did not di¡er signi¢cantly from control
cells (Fig. 1B). In addition to the plasma membrane staining
only some intracellular staining of caveolin-1 co-localizing
with DGV was visible (Fig. 1B). When the £uorescent signal
for caveolin-1 at the apical membrane was quanti¢ed no dif-
ference between control and DGV-infected cells was detected
(135.9 S 3.1 vs. 134.6S 1.4 respectively, arbitrary IF units,
meanSS.E.M.). At the basolateral membrane the signal was
reduced from 132.4S 4.7 to 64.3S 1.6 IF units. Whether this
intracellular retention of caveolin-1 and -2 was due to direct
protein^protein interactions with DGV was addressed by im-
munoprecipitation experiments. Caveolin-1 and caveolin-2
antibodies precipitated characteristic protein doublets corre-
sponding to both caveolins in control cells (Fig. 2A, lanes 1
and 2) [4]. These caveolin doublets were similarly precipitated
from DGV-expressing cells (Fig. 2A, lanes 4 and 5). DGV
could not be detected co-precipitating with either caveolin-1
or -2 antibodies. When DGV was immunoprecipitated by
means of its HA tag, small amounts of a doublet correspond-
ing to the migration of the endogenous caveolins co-precipi-
tated (Fig. 2A, lane 6). When this complex was further ana-
Fig. 1. Caveolin-2 accumulates intracellularly upon DGV expression
in polarized MDCK cells. Immuno£uorescence micrographs of po-
larized MDCK cells infected with recombinant DGV adenovirus at
50% infection frequency. In DGV-expressing cells (red in A and B)
caveolin-2 (A, green) was completely retained intracellularly and
partially co-localized with DGV. The distribution of caveolin-1 (B,
green) was slightly a¡ected. In addition to the plasma membrane
some internal staining partially co-localizing with DGV was de-
tected. Scale bar= 10 Wm.
Fig. 2. Caveolin-1 and -2 co-precipitate with DGV. Control and
DGV-expressing cells were metabolically labelled and lysed in the
presence of Triton X-100 and SDS. A: In control cells, caveolin-1
(lane 1) and caveolin-2 antibodies (lane 2) precipitated characteristic
caveolin doublets while HA antibodies did not precipitate any spe-
ci¢c proteins (lane 3). In DGV-expressing cells, the caveolin dou-
blets were precipitated with caveolin-1 (lane 4) and caveolin-2 (lane
5) antibodies, but both failed to co-precipitate any low molecular
weight proteins corresponding to DGV. HA tag antibodies weakly
co-precipitated the caveolin doublet (lane 6). This doublet was fur-
ther resolved by two-dimensional electrophoresis and could be iden-
ti¢ed as caveolin-1 (arrows) and caveolin-2 (arrowheads) (B).
FEBS 27031 28-2-03 Cyaan Magenta Geel Zwart
U. Lahtinen et al./FEBS Letters 538 (2003) 85^8886
lyzed by two-dimensional gel electrophoresis, it was resolved
to spots representing both caveolin-1 and -2 (Fig. 2B) [4]. The
DGV protein itself was not resolved in isoelectric focusing
gels. Sucrose velocity gradient centrifugation was then used
to analyze whether the DGV peptide becomes incorporated
into the caveolin complexes and whether DGV expression
altered the oligomerization state of the endogenous caveolins.
Caveolin-1 and caveolin-2 were found in large oligomers in
control cells (Fig. 3). In DGV-expressing cells, the amount of
the high molecular weight oligomers of caveolin-2 was re-
duced and most of the protein now co-migrated with the
DGV peptide as lower molecular weight oligomers or mono-
mers (the DGV peptide having a calculated molecular weight
of 12.5 kDa). High molecular weight caveolin-1 homo-oligo-
mers appeared to be una¡ected by DGV expression (Fig. 3).
After immunoprecipitation with caveolin-1 antibodies the
same amounts of caveolin-2 were left in the supernatant
(not immunoprecipitated) of DGV-infected cells as in control
cells (data not shown), indicating that the process of hetero-
oligomerization between caveolin-1 and -2 was not disturbed.
Together these data suggested that the caveolin-1/-2 hetero-
oligomers could not progress into assembling the high molec-
ular weight complexes. Impaired complex formation might
prevent their exit from the Golgi complex and result in intra-
cellular retention [4,23]. In immunoprecipitation experiments
the exposure of epitopes and their accessibility for antibodies,
or weak protein^protein interactions, may have been restrict-
ing for quantitative recovery, and the amount of caveolin-1/-2
co-precipitating with DGV could have been underestimated.
Yet, considering the low amounts of caveolins co-precipitating
with DGV, a direct interaction of DGV with the caveolins
seemed unlikely to be the major cause of these e¡ects. We
also did not ¢nd any indications (e.g. by addition of exoge-
nous cholesterol, changes in cholesterol distribution, or e¡ects
on transport (data not shown)) that DGV would cause a dis-
turbance of cholesterol homeostasis as shown before [17,24].
Since caveolins are known to be involved in the formation
of caveolae [25,26] we quantitated the number of caveolae.
Approximately 1 caveola per Wm membrane length was de-
tected in control cells while in DGV-expressing cells, where
caveolin-1 was still present at the basolateral membrane, the
number of caveolae was drastically reduced (Fig. 4). The po-
tential of caveolin-1 alone to form caveolae has been shown
by expression of caveolin-1 in caveolae-lacking lymphocytes
[25] and by the induction of caveolae on the apical membrane
upon cross-linking of raft proteins in MDCK cells [27]. How-
ever, our current results demonstrate that the caveolin-1/-2
hetero-oligomeric complex is mainly involved in the formation
of basolateral caveolae in MDCK cells. This is further sub-
stantiated by the fact that the number of caveolae in a cav-
eolin-2-over-expressing cell line was signi¢cantly increased
compared to the control cells (Fig. 4B). Interestingly, expres-
Fig. 3. Caveolin-2 oligomerization state is disturbed by DGV ex-
pression. Immunoblots of sucrose density gradient fractions of con-
trol and DGV-expressing cells probed with antibodies against caveo-
lin-1, caveolin-2 and the HA tag of DGV. The corresponding
molecular mass standards are indicated at the bottom. Caveolin-1
was found in both control and DGV-expressing cells in sizes rang-
ing from the monomer size of 21 kDa up to high molecular weight
oligomers of over 600 kDa. In control cells, caveolin-2 was mainly
found in oligomers with a size of approximately 400 kDa. After in-
fection with DGV most of the caveolin-2 was found in low molecu-
lar weight oligomers or in the size range of monomers. DGV was
only found in the low molecular weight range corresponding to
monomers or dimers.
Fig. 4. Intracellular retention of caveolin-2 causes the disappearance of caveolae from the basolateral plasma membrane. Electron micrographs
of ultrathin Epon sections of control cells show the basolateral localization of caveolae (arrows) (A) and the almost complete absence of caveo-
lae in DGV-expressing cells (B). Scale bar= 250 nm. C shows the quantitation of the number of caveolae in control, DGV-expressing, and cav-
eolin-2-over-expressing MDCK cells (clone 54).
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sion of caveolin-1 alone in insect cells leads to the formation
of 50^100 nm vesicular pro¢les while expression of both cav-
eolin-1 and -2 leads to the formation of uniform 45^65 nm
vesicular pro¢les [28]. Co-expression of caveolin-1 and -2 also
leads to the formation of deeper caveolae in human ¢broblasts
than the expression of caveolin-1 alone [29]. We did not ob-
serve a change in size or shape of the caveolae in the caveolin-
2-over-expressing cell line nor did we detect an induction of
apical caveolae (not shown). This is most likely because cav-
eolin-1 is also present in these cells and thus able to make
hetero-oligomeric complexes. Recently a caveolin-2 knock-out
mouse has been described [30]. Interestingly, in these mice
caveolae are still present but they have severe lung disabilities
similar to those described in caveolin-1 knock-out mice [26].
One of the notable ¢ndings in both the caveolin-1 knock-out
mice, which lack caveolae, and the caveolin-2 knock-out mice
is that both caveolin-2 and caveolin-1 levels are decreased
[26,30]. Since it has been shown that the level of expression
of caveolin is important for the formation of caveolae [25],
analysis of the role of individual caveolins in these mice re-
garding the formation of caveolae is complicated. We there-
fore conclude that in MDCK cells caveolin-2 is a limiting or
controlling factor for the biogenesis of basolateral caveolae at
physiological caveolin-1 concentrations.
Acknowledgements: We thank Kim Ekroos and Beate Michel for cell
culture, Patrick Keller for advice with the adenovirus system and Kurt
Anderson for immuno£uorescence quantitation. Masanori Honsho
was partially supported by the Uehara memorial foundation.
References
[1] Wandinger-Ness, A., Bennett, M.K., Antony, C. and Simons, K.
(1990) J. Cell Biol. 111, 987^1000.
[2] Kurzchalia, T.V., Dupree, P., Parton, R.G., Kellner, R., Virta,
H., Lehnert, M. and Simons, K. (1992) J. Cell Biol. 118, 1003^
1014.
[3] Glenney Jr., J.R. (1992) FEBS Lett. 314, 45^48.
[4] Schei¡ele, P., Verkade, P., Fra, A.M., Virta, H., Simons, K. and
Ikonen, E. (1998) J. Cell Biol. 140, 795^806.
[5] Rothberg, K.G., Heuser, J.E., Donzell, W.C., Ying, Y.S., Glen-
ney, J.R. and Anderson, R.G. (1992) Cell 68, 673^682.
[6] Glenney, J.R. and Soppet, D. (1992) Proc. Natl. Acad. Sci. USA
89, 10517^10521.
[7] Scherer, P.E., Lewis, R.Y., Volonte, D., Engelman, J.A., Galbia-
ti, F., Couet, J., Kohtz, D.S., van Donselaar, E., Peters, P. and
Lisanti, M.P. (1997) J. Biol. Chem. 272, 29337^29346.
[8] Parton, R.G. (1996) Curr. Opin. Cell Biol. 8, 542^548.
[9] Kurzchalia, T.V. and Parton, R.G. (1999) Curr. Opin. Cell Biol.
11, 424^431.
[10] Smart, E.J., Graf, G.A., McNiven, M.A., Sessa, W.C., Engel-
man, J.A., Scherer, P.E., Okamoto, T. and Lisanti, M.P. (1999)
Mol. Cell. Biol. 19, 7289^7304.
[11] Ikonen, E. and Parton, R.G. (2000) Tra⁄c 1, 212^217.
[12] Schlegel, A. and Lisanti, M.P. (2001) J. Cell Physiol. 186, 329^
337.
[13] Simons, K. and Ikonen, E. (1997) Nature 387, 569^572.
[14] Sotgia, F., Razani, B., Bonuccelli, G., Schubert, W., Battista, M.,
Lee, H., Capozza, F., Schubert, A.L., Minetti, C., Buckley, J.T.
and Lisanti, M.P. (2002) Mol. Cell. Biol. 22, 3905^3926.
[15] Monier, S., Parton, R.G., Vogel, F., Behlke, J., Henske, A. and
Kurzchalia, T.V. (1995) Mol. Biol. Cell 6, 911^927.
[16] Luetterforst, R., Stang, E., Zorzi, N., Carozzi, A., Way, M. and
Parton, R.G. (1999) J. Cell Biol. 145, 1443^1459.
[17] Pol, A., Luetterforst, R., Lindsay, M., Heino, S., Ikonen, E. and
Parton, R.G. (2001) J. Cell Biol. 152, 1057^1070.
[18] Pimplikar, S.W., Ikonen, E. and Simons, K. (1994) J. Cell Biol.
125, 1025^1035.
[19] He, T.C., Zhou, S., da Costa, L.T., Yu, J., Kinzler, K.W. and
Vogelstein, B. (1998) Proc. Natl. Acad. Sci. USA 95, 2509^
2514.
[20] Parton, R.G. (1995) J. Histochem. Cytochem. 43, 731^733.
[21] Parton, R.G. and Simons, K. (1995) Science 269, 1398^1399.
[22] Vogel, U., Sandvig, K. and van Deurs, B. (1998) J. Cell Sci. 111,
825^832.
[23] Machleidt, T., Li, W.P., Liu, P. and Anderson, R.G. (2000)
J. Cell Biol. 148, 17^28.
[24] Roy, S., Luetterforst, R., Harding, A., Apolloni, A., Etheridge,
M., Stang, E., Rolls, B., Hancock, J.F. and Parton, R.G. (1999)
Nat. Cell Biol. 1, 98^105.
[25] Fra, A.M., Williamson, E., Simons, K. and Parton, R.G. (1995)
Proc. Natl. Acad. Sci. USA 92, 8655^8659.
[26] Drab, M., Verkade, P., Elger, M., Kasper, M., Lohn, M., Lau-
terbach, B., Menne, J., Lindschau, C., Mende, F., Luft, F.C.,
Schedl, A., Haller, H. and Kurzchalia, T.V. (2001) Science 293,
2449^2452.
[27] Verkade, P., Harder, T., Lafont, F. and Simons, K. (2000) J. Cell
Biol. 148, 727^739.
[28] Li, S., Galbiati, F., Volonte, D., Sargiacomo, M., Engelman,
J.A., Das, K., Scherer, P.E. and Lisanti, M.P. (1998) FEBS
Lett. 434, 127^134.
[29] Fujimoto, T., Kogo, H., Nomura, R. and Une, T. (2000) J. Cell
Sci. 113, 3509^3517.
[30] Razani, B., Wang, X.B., Engelman, J.A., Battista, M., Lagaud,
G., Zhang, X.L., Kneitz, B. and Hou Jr., H. (2002) Mol. Cell.
Biol. 22, 2329^2344.
FEBS 27031 28-2-03 Cyaan Magenta Geel Zwart
U. Lahtinen et al./FEBS Letters 538 (2003) 85^8888
